{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:41:50Z","timestamp":1791283310098,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T00:00:00Z","timestamp":1457136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40262-016-0372-9","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T06:27:50Z","timestamp":1457159270000},"page":"991-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias"],"prefix":"10.1007","volume":"55","author":[{"given":"Joe-Elie","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"El-Aissaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Alazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Hulot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Aissaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Le-Heuzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Faisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saik","family":"Urien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,5]]},"reference":[{"key":"372_CR1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00003246-199012000-00015","volume":"18","author":"H Artucio","year":"1990","unstructured":"Artucio H, Pereira M. Cardiac arrhythmias in critically ill patients: epidemiologic study. Crit Care Med. 1990;18:1383\u20138.","journal-title":"Crit Care Med"},{"key":"372_CR2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0002-9149(86)90836-2","volume":"57","author":"DL Packer","year":"1986","unstructured":"Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563\u201370.","journal-title":"Am J Cardiol"},{"key":"372_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.CIR.0000135472.28234.CC","volume":"110","author":"P Nerheim","year":"2004","unstructured":"Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247\u201352.","journal-title":"Circulation"},{"key":"372_CR4","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"European Heart Rhythm Association","year":"2010","unstructured":"European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369\u2013429.","journal-title":"Eur Heart J"},{"key":"372_CR5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, ACC\/AHA Task Force Members, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published erratum appears in Circulation. 2014;130(23):e270\u20131. Circulation. 2014;130:2071\u2013104.","journal-title":"Circulation."},{"key":"372_CR6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/00007611-199608000-00005","volume":"89","author":"A Kumar","year":"1996","unstructured":"Kumar A. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function. South Med J. 1996;89:779\u201385.","journal-title":"South Med J"},{"key":"372_CR7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0002-9149(97)00962-4","volume":"81","author":"HF Clemo","year":"1998","unstructured":"Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81:594\u20138.","journal-title":"Am J Cardiol"},{"key":"372_CR8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s001340050827","volume":"25","author":"A Mayr","year":"1999","unstructured":"Mayr A, Knotzer H, Mutz N, Hasibeder W. Atrial tachyarrhythmia after cardiac surgery. Intensive Care Med. 1999;25:242\u20133.","journal-title":"Intensive Care Med"},{"key":"372_CR9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0735-1097(95)00595-1","volume":"27","author":"E Galve","year":"1996","unstructured":"Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"372_CR10","doi-asserted-by":"crossref","unstructured":"Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29:1149\u201353.","DOI":"10.1097\/00003246-200106000-00011"},{"key":"372_CR11","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","volume":"41","author":"J Carlsson","year":"2003","unstructured":"Carlsson J, Miketic S, Windeler J, STAF Investigators, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"372_CR12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","volume":"347","author":"IC Gelder Van","year":"2002","unstructured":"Van Gelder IC, Hagens VE, Bosker HA, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834\u201340.","journal-title":"N Engl J Med"},{"key":"372_CR13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s001340050627","volume":"24","author":"L Donaldson","year":"1998","unstructured":"Donaldson L, Grant IS, Naysmith MR, Thomas JS. Acute amiodarone-induced lung toxicity. Intensive Care Med. 1998;24:626\u201330.","journal-title":"Intensive Care Med"},{"key":"372_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.CCM.0000151048.72393.44","volume":"33","author":"AE R\u00e4tz-Bravo","year":"2005","unstructured":"R\u00e4tz-Bravo AE, Drewe J, Schlienger RG, Kr\u00e4henb\u00fchl S, Pargger H, Ummenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med. 2005;33:128\u201334 (discussion 245\u20136).","journal-title":"Crit Care Med."},{"key":"372_CR15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11532320-000000000-00000","volume":"33","author":"SA Papiris","year":"2010","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33:539\u201358.","journal-title":"Drug Saf"},{"key":"372_CR16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jcrc.2015.09.002","volume":"30","author":"E Lafont","year":"2015","unstructured":"Lafont E, Urien S, Salem JE, Heming N, Faisy C. Modeling for critically ill patients: an introduction for beginners. J Crit Care. 2015;30:1287\u201394.","journal-title":"J Crit Care"},{"key":"372_CR17","first-page":"309","volume":"33","author":"JL Tonet","year":"1984","unstructured":"Tonet JL, Lechat P, Frank R, et al. Electrocardiographic effects and antiarrhythmic action of 1200\u00a0mg of oral amiodarone per day. Ann Cardiol Angeiol (Paris). 1984;33:309\u201315.","journal-title":"Ann Cardiol Angeiol (Paris)."},{"key":"372_CR18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0002-9149(98)00783-8","volume":"83","author":"GE Kochiadakis","year":"1999","unstructured":"Kochiadakis GE, Igoumenidis NE, Solomou MC, Kaleboubas MD, Chlouverakis GI, Vardas PE. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol. 1999;83:58\u201361.","journal-title":"Am J Cardiol"},{"key":"372_CR19","first-page":"524","volume":"20","author":"M Anastasiou-Nana","year":"1982","unstructured":"Anastasiou-Nana M, Levis GM, Moulopoulos S. Pharmacokinetics of amiodarone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol. 1982;20:524\u20139.","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"key":"372_CR20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/clpt.1985.22","volume":"37","author":"S Pourbaix","year":"1985","unstructured":"Pourbaix S, Berger Y, Desager JP, Pacco M, Harvengt C. Absolute bioavailability of amiodarone in normal subjects. Clin Pharmacol Ther. 1985;37:118\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"372_CR21","unstructured":"Daily Med. Current medication information: amiodarone. http:\/\/dailymed.nlm.nih.gov\/dailymed\/index.cfm . Accessed 1 Dec 2015."},{"key":"372_CR22","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1378\/chest.117.6.1538","volume":"117","author":"PE Vardas","year":"2000","unstructured":"Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538\u201345.","journal-title":"Chest"},{"key":"372_CR23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/01.CIR.62.3.666","volume":"62","author":"A Lotto","year":"1980","unstructured":"Lotto A, Satolli R, Baldini MR. Hemodynamic effects of amiodarone. Circulation. 1980;62:666.","journal-title":"Circulation"},{"key":"372_CR24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/0002-8703(83)90007-8","volume":"106","author":"A Schwartz","year":"1983","unstructured":"Schwartz A, Shen E, Morady F, et al. Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. Am Heart J. 1983;106:848\u201356.","journal-title":"Am Heart J"},{"key":"372_CR25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0002-8703(91)90764-9","volume":"122","author":"WJ Remme","year":"1991","unstructured":"Remme WJ, Kruyssen HA, Look MP, et al. Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J. 1991;122:96\u2013103.","journal-title":"Am Heart J"},{"key":"372_CR26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10928-006-9035-z","volume":"34","author":"P Jacqmin","year":"2007","unstructured":"Jacqmin P, Snoeck E, van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn. 2007;34:57\u201385.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"372_CR27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0735-1097(92)90069-Y","volume":"19","author":"SJ Evans","year":"1992","unstructured":"Evans SJ, Myers M, Zaher C, et al. High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. J Am Coll Cardiol. 1992;19:169\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"372_CR28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1152\/physrev.1991.71.3.617","volume":"71","author":"R Hainsworth","year":"1991","unstructured":"Hainsworth R. Reflexes from the heart. Physiol Rev. 1991;71:617\u201358.","journal-title":"Physiol Rev"},{"key":"372_CR29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/ALN.0b013e318173026f","volume":"108","author":"J-L Fellahi","year":"2008","unstructured":"Fellahi J-L, Parienti J-J, Hanouz J-L, et al. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108:979\u201387.","journal-title":"Anesthesiology"},{"key":"372_CR30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/ALN.0b013e318172fb98","volume":"108","author":"J Butterworth","year":"2008","unstructured":"Butterworth J. Dobutamine: too dangerous for \u201croutine\u201d administration? Anesthesiology. 2008;108:973\u20134.","journal-title":"Anesthesiology"},{"key":"372_CR31","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/hrt.2004.033811","volume":"91","author":"S Miller","year":"2005","unstructured":"Miller S, Crystal E, Garfinkle M, et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart. 2005;91:618\u201323.","journal-title":"Heart"},{"key":"372_CR32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.CCM.0000048627.39686.79","volume":"31","author":"A Mayr","year":"2003","unstructured":"Mayr A, Ritsch N, Knotzer H, et al. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med. 2003;31:401\u20135.","journal-title":"Crit Care Med"},{"key":"372_CR33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jcrc.2011.10.011","volume":"27","author":"S Kanji","year":"2012","unstructured":"Kanji S, Williamson DR, Yaghchi BM, et al. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care. 2012;27:326 (e1\u20138).","journal-title":"J Crit Care."},{"key":"372_CR34","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","volume":"352","author":"BN Singh","year":"2005","unstructured":"Singh BN, Singh SN, Reda DJ, Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861\u201372.","journal-title":"N Engl J Med"},{"key":"372_CR35","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eupc.2005.05.017","volume":"7","author":"C Sticherling","year":"2005","unstructured":"Sticherling C, Behrens S, Kamke W, Stahn A, Zabel M. Comparison of acute and long-term effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Europace. 2005;7:546\u201353.","journal-title":"Europace."},{"key":"372_CR36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/pgmj.59.693.440","volume":"59","author":"L Harris","year":"1983","unstructured":"Harris L, Hind CR, McKenna WJ, et al. Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J. 1983;59:440\u20132.","journal-title":"Postgrad Med J"},{"key":"372_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0167-5273(92)90058-B","volume":"35","author":"G Vietti-Ramus","year":"1992","unstructured":"Vietti-Ramus G, Veglio F, Marchisio U, Burzio P, Latini R. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. Int J Cardiol. 1992;35:77\u201385.","journal-title":"Int J Cardiol"},{"key":"372_CR38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0002-9149(87)90307-9","volume":"60","author":"MA Brodsky","year":"1987","unstructured":"Brodsky MA, Allen BJ, Walker CJ, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987;60:572\u20135.","journal-title":"Am J Cardiol"},{"key":"372_CR39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0735-1097(98)00678-0","volume":"33","author":"GE Kochiadakis","year":"1999","unstructured":"Kochiadakis GE, Igoumenidis NE, Parthenakis FI, Chlouverakis GI, Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1999;33:966\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"372_CR40","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(87)80320-0","volume":"9","author":"ML Greenberg","year":"1987","unstructured":"Greenberg ML, Lerman BB, Shipe JR, Kaiser DL, DiMarco JP. Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol. 1987;9:1148\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"372_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1472-8206.1997.tb00196.x","volume":"11","author":"JC Deharo","year":"1997","unstructured":"Deharo JC, Durand A, Macaluso G, et al. Clinical electrophysiologic effects of a single high oral dose of amiodarone. Fundam Clin Pharmacol. 1997;11:275\u201380.","journal-title":"Fundam Clin Pharmacol"},{"key":"372_CR42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2010.04.020","volume":"106","author":"S Patsilinakos","year":"2010","unstructured":"Patsilinakos S, Christou A, Kafkas N, et al. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent. Am J Cardiol. 2010;106:673\u20136.","journal-title":"Am J Cardiol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0372-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0372-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0372-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T07:41:49Z","timestamp":1567669309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0372-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,5]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0372-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,5]]}}}